Status:
COMPLETED
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Hepatocellular Carcinoma (HCC)
Eligibility:
All Genders
19+ years
Phase:
EARLY_PHASE1
Brief Summary
This investigational study will evaluate if using a combination of TACE along with high dose SBRT would show improvement in local control in patients with Hepatocellular Carcinoma.
Detailed Description
Primary objectives of this research 1. Evaluate the safety of a combination of TACE and high dose SBRT 2. Measure time to progression (TTP) and local recurrence rate of HCC treated with a combination...
Eligibility Criteria
Inclusion
- Diagnosis
- Patients meeting all the following criteria will be considered for enrollment:
- Pathologically confirmed HCC -OR
- HCC greater than 2 cm with classic radiographic findings on 2 separate testing modalities, or an HCC greater than 2 cm with a serum alpha feto-protein greater than 200.
- Lesions:
- Single liver lesion: measuring 3 cm to ≤ 8 cm\*.
- Multiple liver lesions: ≤ 3 liver lesions, none measuring over 5 cm, provided all lesions are considered for TACE.
- Lesions \<3 cm if they are in an unfavorable location for ablation† \*The size criteria of hepatic lesions are also subjected to the dose volume constraints for radiotherapy, as described below.
- Patient
- Patient deemed to not candidate or should have refused liver-transplant, surgery or RFA.
- Patient must be a candidate and receive TACE.
- ECOG (Eastern Cooperative Oncology Group) Zubrod Performance Scale = 0-1.
- Age \> 19
- Patient should not be pregnant. Women of childbearing potential and male participants must practice adequate contraception.
- Adequate hematological profile and adequate liver functions. Signed informed consent document
- Imaging studies completed at least 60 days prior to study entry. Evaluated by radiation oncologist within 2 weeks prior to study entry.
Exclusion
- Patients presenting with any of the following will not be included in the study:
- Prior invasive malignancies
- Prior radiotherapy to the liver or surrounding areas.
- Systemic therapy using any chemotherapy and/or targeted agents given within 2 weeks prior to TACE, during RT, and / or within 3 weeks following RT
- Severe medical co-morbidities
- INR (international normalized ratio) \> 2 times upper level normal
- Uncontrolled or symptomatic clinical ascites
- Major surgical procedure within 3 weeks prior to study entry.
- History of hypersensitivity to chemotherapy agents, contrast material.
- Pregnancy, breast-feeding or planning to become pregnant.
- Treatment with any investigational product in the last 4 weeks before study entry.
- Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
- Patients of Reproductive Potential The patient must not be pregnant or breast-feeding at enrollment in the study. Absence of pregnancy must be demonstrated by serum or urine testing prior to enrollment into the study.
- Female patients of child bearing potential (i.e., ovulating, premenopausal, not surgical sterile) must use a medically accepted contraceptive regimen. Male patients must agree to use a medically approved method of contraception.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01247298
Start Date
October 1 2010
End Date
December 1 2016
Last Update
August 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233